Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

November 17, 2017: By Joan McKenna

A federal judge declared a mistrial Nov. 16 in a federal corruption trial of Florida retina specialist Salomon Melgen and US Sen. Bob Menendez, D-New Jersey, after jurors were unable to reach a verdict. Prosecutors can seek to retry the case.

The trial, overseen by US District Judge William Walls in New Jersey, began Sept. 6. It examined whether Menendez lobbied for Melgen’s business interests in exchange for gifts and political donations.

Defense attorneys built a portrait of their clients as simply friends. Prosecutors alleged that the defendants’ behavior amounted to bribery.

The Justice Department claimed that Menendez intervened to help Melgen try to resolve his $8.9 million billing dispute with Medicare in 2009, after Melgen was accused of overbilling for Lucentis vials. Menendez in return received luxury trips, flights on private jets, and hundreds of thousands of dollars in campaign donations, prosecutors claim.

The judge repeatedly urged jurors to continue deliberating, telling them to “take as much time as you need.”
In a separate trial earlier in 2017, Melgen, 62, was convicted of 67 counts of Medicare fraud. His sentencing hearing was pushed back to December due to the New Jersey trial. Melgen operated the now closed Vitreo-Retinal Consultants of the Palm Beaches.

In that trial, Melgen was accused of falsely diagnosing patients with macular degeneration and other retinal disorders, performing unnecessary procedures, and overcharging for Lucentis by splitting single-use bottles into multiple doses but charging Medicare per patient.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023